Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 21.8% – Should You Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) traded up 21.8% during trading on Tuesday . The company traded as high as $0.49 and last traded at $0.50. 48,603,004 shares were traded during trading, a decline of 43% from the average session volume of 85,729,586 shares. The stock had previously closed at $0.41.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Saturday, January 25th. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Down 12.8 %

The stock has a market cap of $70.08 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The firm’s 50-day simple moving average is $0.29 and its two-hundred day simple moving average is $0.28.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. On average, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.